$PBIO Tech Featured at Leading Food Science Meeting

SOUTH EASTON, MA / September 20, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (”PBI” or the ”Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that its ultra high pressure product line of instruments, methods, and technology platforms was prominently featured at the recent Institute of Food Technologists (”IFT”) annual meeting in Chicago, IL. The Company’s Ultra Shear Technology (”UST”) platform, particularly its U.S. Department of Agriculture-funded collaborative program with The Ohio State University’s College of Food, Agricultural, and Environmental Sciences, was the focus of much discussion during the four-day conference.

Since 1939, IFT has been advancing the application of science across the global food production and supply system, by creating a dynamic forum where individuals from industry, government, and academia spanning more than 90 countries can collaborate, learn, and grow, transforming scientific knowledge into innovative solutions for the benefit of people around the world. The IFT Annual Meeting is the world’s largest annual food science event, with over 20,000 food industry professionals in attendance.

Dr. Aliyar Fouladkhah, Assistant Professor at Tennessee State University (TSU) and Director of the Public Health Microbiology Laboratory (”PHM Lab”) at TSU, said: ”I was the co-chair of a special session on the adoption and validation of high pressure-based technologies by the food industry at the recent IFT annual meeting. My research group presented on the effects of high hydrostatic pressure on the inactivation of foodborne pathogens of major public health concern, such as E. coli, Salmonella, Cronobacter, and Listeria. We believe the data we presented, much of it generated with PBI’s high pressure-based instruments, will assist food safety researchers and stakeholders worldwide as they consider the use of pressure-based interventions for their microbiological studies.”

The research programs at the Fouladkhah and PHM Laboratories at TSU primarily focus on the development of methods to improve microbial safety of various food products. Recent enhancements in the commercial feasibility of high-pressure processing (HPP) have been pivotal in the development of new methods for ensuring food safety, while preserving important sensory experience and quality factors. According to Dr. Fouladkhah, the studies that his research teams have completed using PBI’s ultra-high pressure instruments have proven extremely valuable in determining the critical effects of pressure on the most prevalent foodborne pathogens of public health concern, such as various Salmonella serovars, Shiga toxin-producing Escherichia coli serogroups, and serotypes of Listeria monocytogenes.

Dr. Nate Lawrence, PBI’s Vice President of Marketing and Sales, said: ”We were delighted with the opportunity to attend, participate in scientific sessions, and exhibit at IFT 2018. We had two major goals for this meeting. First, to showcase our growing product line of pressure-based instruments and consumables to food science researchers. We knew Dr. Fouladkhah had been invited to present data in several forums, including as co-chair of the special session of pressure-based technologies for the food science industry. We channeled this exposure into an opportunity to showcase our products to a very large market that had rarely been exposed to PBI and our pressure-based technology platforms and products before. Secondly, with a ”who’s who” list of attendees, we wanted to have meaningful discussions with key opinion leaders (”KOLs”) in the food science area regarding our newly patented Ultra Shear Technology platform.”

Dr. Fouladkhah commented: ”I am confident that the food science community will require and embrace a continued flow of next-generation equipment, technologies and methods for years to come. I believe PBI’s Ultra-Shear Technology (UST) platform, which I first observed in detail at IFT 2018, may be one such technology. Currently in development, UST offers the potential to greatly benefit the food and many other industries, as it could conceivably inactivate the most resistant pathogenic organisms in food matrix, resulting in safer and more stable products. In addition, it appears this new, cutting-edge technology could also be used to produce stable nanoemulsions, resulting in products that could look and taste great, have extended shelf-life at room temperature, but not require chemical preservation. I look forward with anticipation to expanding the capability of my research program by receiving one of PBI’s first UST systems, which I believe will greatly advance our team’s mission to help make food and beverages safer and more desirable for everyone.”

Mr. Richard T. Schumacher, President and CEO of PBI, said: ”Our assessment was that IFT 2018 was a highly successful meeting for PBI. Related to our first major goal, we came back from the meeting with a list of food science researchers interested in learning more about how our products could better enable their research programs. Related to our second major goal, we had the opportunity to discuss the power and potential of the UST platform with KOLs in industry, government, and academia worldwide. We learned a lot, met many important and knowledgeable leaders and food industry stakeholders, and had the opportunity to deeply examine current competitive technology platforms. Based on what we learned, we have made several very important decisions concerning the opportunity for and future path of our UST program. As our action path unfolds, further highlights of these decisions will be made public over the coming weeks.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or ”PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (”UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)

Nathan P. Lawrence, Ph.D., VP of Marketing and Sales (508) 230-1829 (F)